FacebookTwitterGoogle+RedditEmail

The Big HRT

A reduction in a jury award for a drug that caused cancer from $134 million to $58 million would not normally be cause to rejoice. But it has not been a normal year for hormone maker Wyeth.

The Madison, N.J. based drug company faces 5,300 Prempro and Premarin related law suits in addition to the one it just lost–but with damages reduced–in Reno, NV brought by three women with breast cancer.

Wyeth had asked Washoe District Judge Robert Perry for a mistrial.

Selling a product that’s proven to cause cancer isn’t easy for Wyeth.

In January, it announced it was selling the one million square-foot Rouses Point, N.Y plant where it made its horse-urine derived drugs and employed 900 and cutting a full ten percent of its work force.

Nor is the Food and Drug Administration (FDA) rubber stamping new drugs from the company which made fenfluramine/phentermine and some say has a “safety second” culture.

Last year it rejected Wyeth’s osteoporosis drug, bazedoxifene, because of stroke and blood clot problems, schizophrenia drug, bifeprunox, because it was not as effective as other drugs on the market and menopause drug, Pristiq, because of serious heart or liver complications experienced by trial participants.

The FDA is “establishing monopolies” by rejecting drugs just because they’re inferior to existing ones growled outgoing Wyeth CEO Bob Essner when bifeprunox was not approved. After all, the public liked Vioxx and Vytorin just fine and they weren’t better than their predecessors, he might have been thinking.
No wonder Wyeth lawyers have been browbeating the FDA, successfully it turns out, to regulate pharmacy compounded bioidentical hormones that have unseated its products in many women’s medicine chests.

Wyeth is not alone in hoping for an HRT comeback.

Since HRT was found by the Women’s Health Initiative in 2002 to cause a 26 percent increased risk of breast cancer, 29 percent increased risk of heart attack, 41 percent increased risk of stroke and 100 percent increased risk of blood clots, a study in the January issue of Cancer Epidemiology, Biomarkers and Prevention found the cancers also move quickly.

Women who took combined estrogen/progestin hormone-replacement therapy for just three years had four times the usual risk of lobular breast cancer which accounts for about 10 percent of invasive breast cancer.

The effect of millions of HRT users saying, “You want us to take WHAT?” after the WHI study–75 percent quit–was also dramatic. There was an 8.6 percent reduction in overall breast cancer between 2001 and 2004 and 14.7 reduction for estrogen-receptor positive breast cancer.

But “studies” by doctors who don’t want to give up the HRT gravy train appear with increasing regularity, promoting results that seek to reverse or spin the WHI findings.

HRT actually protects against heart disease and reduces calcification of the arteries–two original, disproved HRT selling points–say the authors of the new crop of “timing hypothesis/therapeutic window of opportunity” analyses, hoping the memory of the American public is as short as their practice’s funds without trumped up HRT profits.

Researchers even resuscitated the discredited claim that HRT protects against dementia at a meeting of the American Academy of Neurology last year. And there are rumblings that HRT’s ability to lower colon cancer could be of value. (Viz: HRT causes breast cancer, heart attack, stroke and blood clots but you might not get colon cancer!)

Of course some doctors have noted the creeping HRT revisionism.

Enthusiasm for the Yes But studies “far exceeds the science” and does not “alter current recommendations that hormone therapy should never be used to prevent heart disease,” says Dr. Helen Roberts, senior lecturer in women’s health at Auckland University. For one thing, “the risk of stroke was elevated regardless of how many years had elapsed since menopause,” she says of the new studies.

But others like the American Association of Clinical Endocrinologists (AACE) have jumped on the HRT bandwagon.

“This is an important and meaningful analysis for women who can benefit from Hormone Replacement Therapy,” said Richard Hellman, AACE President about a study which indicated HRT did not elevate cardiovascular disease risk in some women.

And a position paper on the AACE site says, “Given the powerful effects of estrogen therapy in relieving menopausal symptoms, we believe that physicians may safely counsel women to use estrogen for the relief of menopausal symptoms.”

Some suggest Wyeth money is behind the AACE position.

After all, Hellman also came out for controversial diabetes drug Avandia when the FDA questioned the drug’s safety. “There is still not a good scientific basis for assessing the drug’s safety in all patients. But, we can say, if there is an increased risk for a heart attack, it appears to be a relatively small risk,” he wrote on the AACE site.

And even though he added the organization has “no financial ties to the company, GlaxoSmithKline that manufactures Avandia,” AACE’s annual report for 2006-2007 thanks GlaxoSmithKline four times for its financial support.

Wyeth money could help for future court cases.

 

 

 

 

More articles by:

Martha Rosenberg is an investigative health reporter. She is the author of  Born With A Junk Food Deficiency: How Flaks, Quacks and Hacks Pimp The Public Health (Prometheus).

November 19, 2018
David Rosen
Amazon Deal: New York Taxpayers Fund World Biggest Sex-Toy Retailer
Sheldon Richman
Art of the Smear: the Israel Lobby Busted
Chad Hanson
Why Trump is Wrong About the California Wildfires
Dean Baker
Will Progressives Ever Think About How We Structure Markets, Instead of Accepting them as Given?
Robert Fisk
We Remember the Great War, While Palestinians Live It
Dave Lindorff
Pelosi’s Deceptive Plan: Blocking any Tax Rise Could Rule Out Medicare-for-All and Bolstering Social Security
Rick Baum
What Can We Expect From the Democrat “Alternative” in California?
Thomas Scott Tucker
Trump, World War I and the Lessons of Poetry
John W. Whitehead
Red Flag Gun Laws
Newton Finn
On Earth, as in Heaven: the Utopianism of Edward Bellamy
Robert Fantina
Shithole Countries: Made in the USA
René Voss
Have Your Say about Ranching in Our Point Reyes National Seashore
Weekend Edition
November 16, 2018
Friday - Sunday
Jonah Raskin
A California Jew in a Time of Anti-Semitism
Andrew Levine
Whither the Melting Pot?
Joshua Frank
Climate Change and Wildfires: The New Western Travesty
Nick Pemberton
The Revolution’s Here, Please Excuse Me While I Laugh
T.J. Coles
Israel Cannot Use Violent Self-Defense While Occupying Gaza
Rob Urie
Nuclear Weapons are a Nightmare Made in America
Paul Street
Barack von Obamenburg, Herr Donald, and Big Capitalist Hypocrisy: On How Fascism Happens
Jeffrey St. Clair
Roaming Charges: Fire is Sweeping Our Very Streets Today
Aidan O'Brien
Ireland’s New President, Other European Fools and the Abyss 
Pete Dolack
“Winners” in Amazon Sweepstakes Sure to be the Losers
Richard Eskow
Amazon, Go Home! Billions for Working People, But Not One Cent For Tribute
Ramzy Baroud
In Breach of Human Rights, Netanyahu Supports the Death Penalty against Palestinians
Brian Terrell
Ending the War in Yemen- Congressional Resolution is Not Enough!
John Laforge
Woolsey Fire Burns Toxic Santa Susana Reactor Site
Ralph Nader
The War Over Words: Republicans Easily Defeat the Democrats
M. G. Piety
Reading Plato in the Time of the Oligarchs
Rafael Correa
Ecuador’s Soft Coup and Political Persecution
Brian Cloughley
Aid Projects Can Work, But Not “Head-Smacking Stupid Ones”
David Swanson
A Tale of Two Marines
Robert Fantina
Democrats and the Mid-Term Elections
Joseph Flatley
The Fascist Creep: How Conspiracy Theories and an Unhinged President Created an Anti-Semitic Terrorist
Joseph Natoli
Twitter: Fast Track to the Id
William Hawes
Baselines for Activism: Brecht’s Stance, the New Science, and Planting Seeds
Bob Wing
Toward Racial Justice and a Third Reconstruction
Ron Jacobs
Hunter S. Thompson: Chronicling the Republic’s Fall
Oscar Gonzalez
Stan Lee and a Barrio Kid
Jack Rasmus
Election 2018 and the Unraveling of America
Sam Pizzigati
The Democrats Won Big, But Will They Go Bold?
Yves Engler
Canada and Saudi Arabia: Friends or Enemies?
Cesar Chelala
Can El Paso be a Model for Healing?
Mike Ferner
The Tragically Misnamed Paris Peace Conference
Barry Lando
Trump’s Enablers: Appalling Parallels
Ariel Dorfman
The Boy Who Taught Me About War and Peace
FacebookTwitterGoogle+RedditEmail